Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)
- Conditions
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 126
- Registration Number
- NCT02292537
- Locations
- 🇺🇸
UCLA Clinical and Translational Research Center, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 156
- Registration Number
- NCT02283853
- Locations
- 🇧🇬
MHATNP 'Sv.Naum', EAD, Sofia, Bulgaria
🇮🇱Chaim Sheba Medical Center, Ramat Gan, Israel
🇫🇷Hopital Roger Salengro - CHU Lille, Lille Cedex, Nord, France
Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery
- Conditions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 467
- Registration Number
- NCT02283918
- Locations
- 🇺🇸
Research Site, Akron, Ohio, United States
🇮🇹Research site, Roma, Italy
Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT02269930
- Locations
- 🇺🇸
Research Site, Evansville, Indiana, United States
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 47
- Registration Number
- NCT02241785
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
- Conditions
- Interventions
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Biogen
- Registration Number
- NCT02234869
Plegridy Observational Program
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1208
- Registration Number
- NCT02230969
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
🇩🇰Research site, Glostrup, Denmark
Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 12
- Registration Number
- NCT02228395
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 56
- Registration Number
- NCT02228707
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 646
- Registration Number
- NCT02219932
- Locations
- 🇷🇺
Research Site, Nizhny Novgorod, Russian Federation
🇬🇧Research site, Nottingham, United Kingdom